Russia plans low-tech fake drug crackdown

13 August 2006

The Russian Duma is planning to debate a new drug law in the fall that would "ban the flow of medicines into retail without using technologies that protect medicines from counterfeiting," according to Duma Speaker Boris Gryzlov.

His statement was supported by Veniamin Monblit, research director at Comcon, the Moscow-based market research firm, who said: "the equipment for manufacturing medicine is expensive and complex. It cannot be installed at a dacha or in some shed." Mr Monblit added that eliminating the threat of counterfeits was "absolutely not a matter of technology."

Because the Russian government's approach is to consider that fake drugs are often produced on the same assembly lines that manufacture legitimate products, it believes that special labels, similar to those recently introduced in Russia for alcoholic drinks, are the only realistic identifiers, given that providing pharmacies with the equipment to employ sophisticated tracking or tagging is logistically unrealistic at the present time.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight